Co-Diagnostics (Co-Diagnostics) Cash And Cash Equivalents

: $14.92 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Co-Diagnostics's quarterly cash and cash equivalents declined from Jun. 2023 ($13.83 Mil) to Sep. 2023 ($10.24 Mil) but then increased from Sep. 2023 ($10.24 Mil) to Dec. 2023 ($14.92 Mil).

Co-Diagnostics's annual cash and cash equivalents declined from Dec. 2021 ($88.61 Mil) to Dec. 2022 ($22.97 Mil) and declined from Dec. 2022 ($22.97 Mil) to Dec. 2023 ($14.92 Mil).

Co-Diagnostics Cash And Cash Equivalents Historical Data

The historical data trend for Co-Diagnostics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

0.89

42.98

88.61

22.97

14.92

Co-Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																22.97	6.36	13.83	10.24	14.92

Co-Diagnostics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Co-Diagnostics (NAS:CODX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Co-Diagnostics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Co-Diagnostics (Co-Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

C97:Germany

Address

2401 South Foothill Drive, Salt Lake City, UT, USA, 84109

Website

https://www.codiagnostics.com

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

Executives

Brian Lee Brown	officer: Chief Financial Officer	5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy	director	64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard	director	2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan	director, officer: CEO and President	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson	director	26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson	officer: CFO and Secretary	7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy	director	2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield	director, officer: Chief Science Officer	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc	10 percent owner	1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner	director	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc	10 percent owner	8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc	10 percent owner	4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124